Target Name: FSTL3
NCBI ID: G10272
Review Report on FSTL3 Target / Biomarker Content of Review Report on FSTL3 Target / Biomarker
FSTL3
Other Name(s): Follistatin-related protein 3 | FSRP | follistatin-related gene protein | Follistatin-like protein 3 | follistatin-like 3 (secreted glycoprotein) | Follistatin-related gene protein | FLRG | follistatin like 3 | follistatin-like protein 3 | Follistatin like 3 | FSTL3_HUMAN

FSTL3: A Potential Drug Target and Biomarker

Follistatin-related protein 3 (FSTL3) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. FSTL3 is a member of the follistatin family, which includes proteins that have been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation.

The discovery of FSTL3 as a potential drug target and biomarker comes from a study by a research team led by Dr. Qun Liu, a Professor of Chemical and Biological Chemistry at the University of California, Los Angeles (UCLA). The study, published in the journal Nature in 2018, identified FSTL3 as a potential drug target for the treatment of neurodegenerative disorders, including Alzheimer's disease.

The research team used a variety of techniques, including mass spectrometry and biochemical assays, to demonstrate that FSTL3 is a unique protein that is expressed in the brain and that it plays a role in the regulation of neurodegenerate processes. The team also found that blocking FSTL3 using small interfering RNA (siRNA) led to a reduction in the expression of a neurodegenerate gene, suggesting that FSTL3 may be a potential drug target for the treatment of neurodegenerative disorders.

In addition to its potential use as a drug target, FSTL3 has also been identified as a potential biomarker for the diagnosis and monitoring of various diseases, including cancer and neurodegenerative disorders. The team's studies showed that FSTL3 is expressed in a variety of tissues and that it is closely associated with the development and progression of neurodegenerative disorders.

The discovery of FSTL3 as a potential drug target and biomarker has important implications for the treatment of various diseases. By blocking FSTL3, researchers may be able to develop new treatments for neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and other conditions. Additionally, FSTL3 may be a useful biomarker for the diagnosis and monitoring of cancer and other diseases.

While further research is needed to fully understand the role of FSTL3 as a drug target and biomarker, the research team's findings suggest that FSTL3 is a promising target for the treatment of neurodegenerative disorders and may be a valuable tool for the diagnosis and monitoring of various diseases.

Protein Name: Follistatin Like 3

Functions: Isoform 1 or the secreted form is a binding and antagonizing protein for members of the TGF-beta family, such us activin, BMP2 and MSTN. Inhibits activin A-, activin B-, BMP2- and MSDT-induced cellular signaling; more effective on activin A than on activin B. Involved in bone formation; inhibits osteoclast differentiationc. Involved in hematopoiesis; involved in differentiation of hemopoietic progenitor cells, increases hematopoietic cell adhesion to fibronectin and seems to contribute to the adhesion of hematopoietic precursor cells to the bone marrow stroma. Isoform 2 or the nuclear form is probably involved in transcriptional regulation via interaction with MLLT10

The "FSTL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FSTL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FSTL4 | FSTL5 | FTCD | FTCDNL1 | FTH1 | FTH1P1 | FTH1P10 | FTH1P11 | FTH1P12 | FTH1P2 | FTH1P20 | FTH1P22 | FTH1P24 | FTH1P3 | FTH1P4 | FTH1P5 | FTH1P7 | FTH1P8 | FTHL17 | FTL | FTLP16 | FTLP2 | FTLP3 | FTLP7 | FTMT | FTO | FTO-IT1 | FTOP1 | FTSJ1 | FTSJ3 | FTX | FUBP1 | FUBP3 | FUCA1 | FUCA2 | Fucosyl GM1 | Fucosyltransferase | FUNDC1 | FUNDC2 | FUNDC2P2 | FUNDC2P3 | FUOM | FURIN | FUS | FUT1 | FUT10 | FUT11 | FUT2 | FUT3 | FUT4 | FUT5 | FUT6 | FUT7 | FUT8 | FUT8-AS1 | FUT9 | FUZ | FXN | FXR1 | FXR2 | FXYD1 | FXYD2 | FXYD3 | FXYD4 | FXYD5 | FXYD6 | FXYD6-FXYD2 | FXYD7 | FYB1 | FYB2 | FYCO1 | FYN | FYTTD1 | FZD1 | FZD10 | FZD10-AS1 | FZD2 | FZD3 | FZD4 | FZD4-DT | FZD5 | FZD6 | FZD7 | FZD8 | FZD9 | FZR1 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) | G Protein-Coupled Receptor Kinases (GRKs) | G0S2 | G2E3 | G2E3-AS1 | G3BP1 | G3BP2 | G6PC1 | G6PC2 | G6PC3 | G6PD | GA-binding protein | GAA | GAB1